Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis
© Tanabe et al; licensee BioMed Central Ltd. 2010
Received: 2 March 2010
Accepted: 19 May 2010
Published: 19 May 2010
We performed a single-institution retrospective study to evaluate the efficacy and toxicities of combination therapy with docetaxel and S-1 in patients with advanced or recurrent gastric cancer.
Eighty-six patients with advanced or recurrent gastric cancer were enrolled. Patients received docetaxel, 40 mg/m2, on day 1 and oral S-1, 80 mg/m2/day, on days 1 to 14 every 3 weeks.
All 84 patients were assessable for response. The overall response rate was 52.4% (44/84) and the disease control rate was 96.4% (81/84). Median time to progression (TTP) and overall survival (OS) were 6.5 (95% CI, 4.8-8.1 months) and 15.1 months (95% CI, 11.7-18.5 months), respectively. The major toxicities were neutropenia, leukopenia, alopecia and anorexia. Grade 3 or 4 hematologic toxicities included neutropenia in 31 patients (36.0%), leukopenia in 27 (31.7%), febrile neutropenia in four (4.7%), and anemia in one (1.2%). Other grade 3 toxicities included anorexia in five patients (5.8%), and stomatitis, diarrhea and nausea in one each (1.2%). There was one treatment-related death (1.2%).
The combination of docetaxel and S-1 had good clinical activity with acceptable toxicity in patients with advanced or recurrent gastric cancer.
Worldwide, gastric cancer ranks second among causes of all cancer-related deaths, with about 700,000 confirmed mortalities annually . In Japan, gastric cancer is still the second most frequent cause of cancer-related death, despite advances in diagnosis and treatment. For patients with unresectable or recurrent gastric cancer, outcomes are extremely poor, with a median survival time, if untreated, of 3 to 5 months [2, 3]. Many randomized controlled trials of various treatment regimens have been reported, including 5-fluorouracil, doxorubicin, and mitomycin (FAM) , epirubicin and cisplatin (CDDP) in combination with continuous infusion of 5-fluorouracil (ECF) , and 5-fluorouracil and cisplatin (FP) , but all produced median survivals of less than 1 year. No world-wide standard regimen has as yet been established.
Recently, two randomized controlled trials were reported from Japan [7, 8]. One was the JCOG9912 trial, which showed S-1 to be non-inferior to continuous infusion of 5-fluorouracil with respect to overall survival (OS). Another was the SPIRITS trial, which revealed S-1 plus CDDP to be superior to S-1 alone with respect to OS. In clinical practice, S-1 plus CDDP has been recognized as the standard chemotherapy regimen for advanced or recurrent gastric cancer in Japan.
Docetaxel has shown promising activity in gastric cancer, both as monotherapy  and in combination with other agents [10–12]. We performed phase I and phase II studies of combination therapy with docetaxel and S-1 for patients with advanced or recurrent gastric cancer [13, 14]. In the phase II study, the overall response rate was 56.3% (95% CI, 38-66%) and median survival time was 14.3 months (95% CI, 10.7-20.3 months). The most common severe toxicities were neutropenia (58.3%), leukopenia (41.7%), anorexia (14.6%) and stomatitis (8.3%). These findings suggested the regimen combining docetaxel with S-1 to be a promising first line therapy for advanced or recurrent gastric cancer. On the basis of this assumption, the objectives of the current study were to retrospectively clarify the efficacy and toxicities of the docetaxel and S-1 combination as a first-line treatment for patients with advanced or recurrent gastric cancer and to analyze prognostic factors in these patients.
Patients and methods
The subjects of this study were 86 patients treated between August 2001 and September 2009 at the Hiroshima University Hospital. Patients were eligible for this study if they had histologically confirmed advanced or recurrent gastric cancer, no prior therapy, including adjuvant therapy, Eastern Cooperative Oncology Group (ECOG) performance status <3, age ≧20 years, adequate organ function, and life expectancy of 3 months or more. Written informed consent was obtained from all patients prior to enrollment in the study according to institutional guidelines.
S-1, at 80 mg/m2, was orally administered twice daily for 2 weeks, followed by a drug-free interval of 1 week (one cycle). The docetaxel infusion was started simultaneously with S-1 administration. Dexamethasone, 8 mg, was infused 1 hour before docetaxel administration. The dose of S-1 was reduced by 25% up to 50 mg/m2 in the event of any of the following toxicities during the previous treatment cycle: grade 4 leukopenia or neutropenia; thrombocytopenia ≧grade 3; and nonhematologic toxicity ≧grade 3 except anorexia, nausea, and vomiting. There were no dose reductions for docetaxel. Treatment with both S-1 and docetaxel was delayed for up to 3 weeks if patients had insufficient hepatic, cardiac, renal, or bone marrow function. (i.e., WBC <3,000/mm3, neutrophils <1,500/mm3, platelets <100,000/mm3, fever <38°C with grade 3 to 4 neutropenia, or nonhematologic toxicity ≧grade 3) Cycles were repeated every 3 weeks, and the treatment was continued until disease progression, unacceptable toxicity, or the patient refused further therapy.
Evaluation of efficacy and toxicities
Responses were classified according to Response Evaluation Criteria In Solid Tumors (RECIST) guidelines . Tumor size was measured by CT scan with a 5 mm slice thickness for all measurable lesions to assess responses every 4 to 6 weeks. Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 .
OS was calculated from the date of chemotherapy initiation to the date of all-cause death or the latest follow-up. Time to progression (TTP) was calculated from the date of chemotherapy to the first day of disease progression. The median OS and TTP were estimated using the Kaplan-Meier method. Multivariate analysis of prognostic factors was performed by the Cox proportional hazard method to evaluate the influences of prognostic factors on patient survival. A P < 0.05 was considered to indicate a statistically significant difference.
No. of patients (%)
Assemble for response
Assemble for toxicity
Performance status by ECOG
No. of organs involved
Tumor response and survival
No. of patients
Hematologic and non-hematologic toxicities
Grade of toxicities
% of Grade
3 or 4
Prognostic factor analysis (univariate).
11.5 - 19.0
7.1 - 18.4
9.8 - 14.8
10.7 - 22.8
0 - 16.5
11.7 - 18.8
9.1 - 15.1
9.1 - 18.2
11.0 - 18.2
No. of organs involved
10.1 - 15.4
14.4 - 19.3
12.7 - 19.3
3.5 - 17.3
9.5 - 20.7
11.1 - 18.1
No (SD or PD)
6.0 - 11.2
12.7 - 23.7
4.2 - 13.0
15.0 - 17.5
Multivariate analyss of overall survival.
0.867 - 5.073
0.253 - 0.732
0.495 - 1.476
A variety of treatment regimens have been developed [4–6] and have improved the survival of patients with advanced or recurrent gastric cancer. Currently, combination chemotherapy is considered to be more effective than single-agent therapy. S-1 is an oral antitumor drug that is composed of tegafur, 5-chloro-2,4 dihydroxypyrimidine and potassium oxonate. This drug was designed to enhance the efficacy and reduce the gastrointestinal toxicity of tegafur, a pro-drug of fluorouracil [17–19]. S-1 mono-therapy reportedly achieved a response rate of 45% and 2-year survival rate of 17% [18, 20]. In the SPIRITS trial , the combination of S-1 and CDDP showed encouraging results as compared to S-1 alone, with response rates of 54% to 31% and OS of 13 months to 11 months. However, the results of the GC0301/TOP 002 (S-1 vs S-1 + CPT-11) revealed that OS with combination therapy did not significantly exceed that with mono-therapy . Other agents for use in combination with S-1, such as taxans, should also be evaluated.
The main rationales for combination treatment with docetaxel and S-1 were synergistic antitumor activity in vivo and lack of overlapping toxicities . We previously demonstrated the mechanisms underlying the synergistic effects of docetaxel with S-1 . The expressions of thymidylate synthase and dihidropyrimidine dehydrogenase were decreased and that of orotate phosphorybosyl transferase was increased when docetaxel was administered in combination with S-1. In addition, in recent retrospective and phase I/II study [13, 14, 24], the combination therapy demonstrated promising results for highly activity and manageable toxicity as first-line regimen for advanced or recurrent gastric cancer.
In this study, combination therapy with docetaxel and S-1 showed good clinical activity with acceptable toxicity in patients with advanced or recurrent gastric cancer. The overall response rate was 52.4%, median TTP 6.5 months, and median OS 15.1 months. The major toxicities were leucopenia (52.3%), alopecia (46.5%), neutropenia (45.3%) and anorexia (41.8%), respectively. Grade 3 or 4 hematologic toxicities included neutropenia (36.0%), leucopenia (31.7%), febrile neutropenia (4.7%) and anemia (1.2%), which occurred in 55.6% (40/72) within three cycles. However, the hematological and non-hematological toxicities were both tolerable, except in one case which died due to Grade 4 neutropenia followed by sepsis, and most subjects could be treated as outpatients. This present results were compatible with those of a previously reported Phase I/II study. Herein, we also found the tumor response to be a prognostic factor indicating increased OS, while other independent factors, such as performance status, disease status and histology metastatic sites, did not affect survival. Second-line chemotherapy also didn't contribute to the favorable OS in this study. There is no established second-line chemotherapy for gastric cancer, but some randomized phase II or III study are now ongoing, such as JACCRO GC-05: the romdomized phase II/III study comparing CPT-11 monotherapy with the S-1/CPT-11 combination for S-1 refractaory gastric cancer. Based on these promising results, a phase III study (JACCRO GC03 study)  comparing S-1 alone versus the combination of docetaxel and S-1 has been launched. This is a prospective, multicenter, multinational, randomized study of patients with advanced gastric cancer. The primary objective of the study is to compare median OS with the combination therapy (docetaxel and S-1) to that in the control arm (S-1 alone). In total, 638 patients were enrolled (the original goal was 628 patients, 314 in each treatment arm), and the final results will be reported in 2010. Depending on the results of the GC03 study, this combination regimen may become a first-line standard therapy for patients with advanced or recurrent gastric cancer.
In conclusion, our retrospective study demonstrated that the docetaxel and S-1 combination has good clinical activity with acceptable toxicity when administered as a first-line treatment for patients with advanced or recurrent gastric cancer.
- Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24: 2137-2150. 10.1200/JCO.2005.05.2308.View ArticlePubMedGoogle Scholar
- Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M: modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric-cancer. Cancer. 1993, 72: 37-41. 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995, 71: 587-591.PubMed CentralView ArticlePubMedGoogle Scholar
- Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980, 93: 533-536.View ArticlePubMedGoogle Scholar
- Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994, 5: 609-616.PubMedGoogle Scholar
- Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S, Japan Clinical Oncology Group Study (JCOG9205): Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003, 21: 54-59. 10.1200/JCO.2003.04.130.View ArticlePubMedGoogle Scholar
- Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology. 2009, 10: 1063-1069. 10.1016/S1470-2045(09)70259-1.View ArticlePubMedGoogle Scholar
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology. 2008, 9: 215-221. 10.1016/S1470-2045(08)70035-4.View ArticlePubMedGoogle Scholar
- Einzig AI, Neuberg D, Remick SC, Karp DD, Odwyer PJ, Stewart JA, Benson AB: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol. 1996, 13: 87-93. 10.1007/BF02993858.View ArticlePubMedGoogle Scholar
- Thuss-Patience PC, Kretzschmar A, Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol. 2006, 2: 603-620. 10.2217/147966188.8.131.523.View ArticlePubMedGoogle Scholar
- Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs. 2009, 20: 752-756. 10.1097/CAD.0b013e32832ec02b.View ArticlePubMedGoogle Scholar
- Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009, 64: 877-883. 10.1007/s00280-009-0936-6.View ArticlePubMedGoogle Scholar
- Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res. 2004, 24: 1843-1851.PubMedGoogle Scholar
- Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006, 12: 3402-3407. 10.1158/1078-0432.CCR-05-2425.View ArticlePubMedGoogle Scholar
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016/j.ejca.2008.10.026.View ArticlePubMedGoogle Scholar
- Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003, 13: 176-181. 10.1016/S1053-4296(03)00031-6.View ArticlePubMedGoogle Scholar
- Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996, 56: 2602-2606.PubMedGoogle Scholar
- Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000, 58: 191-197. 10.1159/000012099.View ArticlePubMedGoogle Scholar
- Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998, 13: 693-698.PubMedGoogle Scholar
- Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998, 34: 1715-1720. 10.1016/S0959-8049(98)00211-1.View ArticlePubMedGoogle Scholar
- Imamura H, Iishi H, Tsuburaya A, Hatake K, Imamoto HME: Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Gastrointestinal Cancer Symposium. 2008, Abstract #5:Orland, USA.Google Scholar
- Neste Van Den E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M: A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 2000, 6: 64-71.Google Scholar
- Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006, 119: 783-791. 10.1002/ijc.21879.View ArticlePubMedGoogle Scholar
- Tsutani Y, Ohara M, Suzuki T, Minami K, Miyahara E, Kameda A, Noso Y: Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer. Anticancer Res. 2009, 29: 2775-2779.PubMedGoogle Scholar
- Fujii M: Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). International Journal of Clinical Oncology. 2008, 13: 201-205. 10.1007/s10147-008-0775-1.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.